Literature DB >> 24974387

Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial.

Paulette D Chandler1, Edward L Giovannucci2, Jamil B Scott3, Gary G Bennett4, Kimmie Ng5, Andrew T Chan6, Bruce W Hollis7, Karen M Emmons8, Charles S Fuchs5, Bettina F Drake9.   

Abstract

BACKGROUND: Black men exhibit a high prevalence of vitamin D deficiency as well as a higher incidence of prostate cancer and higher mortality rates from prostate cancer than Whites. There are few data about the effect of vitamin D3 (cholecalciferol) supplementation on prostate-specific antigen (PSA) in healthy Black men.
METHODS: During three winters from 2007 to 2010, 105 Black men (median age, 48.9 years) of Boston, MA were randomized into a four-arm, double-blind trial for 3 months of placebo, 1,000, 2,000, or 4,000 U of vitamin D3. At baseline and 3 months, free and total PSA was measured.
RESULTS: With vitamin D supplementation, no significant differences in free and total PSA were observed; free PSA, -0.0004 ng/mL (P = 0.94) and total PSA, -0.004 ng/mL (P = 0.92) for each additional 1,000 U/d of vitamin D3.
CONCLUSION: Within an unselected population of healthy Black men without a cancer diagnosis, we found no effect of vitamin D supplementation on free or total PSA. IMPACT: These findings support prior findings of no change in PSA with vitamin D supplementation and emphasize the need for new methods to assess the influence of vitamin D supplementation on prostate cancer prevention. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24974387      PMCID: PMC4167903          DOI: 10.1158/1055-9965.EPI-14-0522

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  15 in total

1.  Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells.

Authors:  Erik J Tokar; Mukta M Webber
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer.

Authors:  Gary G Schwartz; M Craig Hall; Diana Stindt; Suzanne Patton; James Lovato; Frank M Torti
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

3.  Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)

Authors:  C Gross; T Stamey; S Hancock; D Feldman
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

4.  Vitamin D and prostate cancer: the role of membrane initiated signaling pathways in prostate cancer progression.

Authors:  Sandra Karlsson; Josefin Olausson; Dan Lundh; Peter Sögård; Abul Mandal; Kjell-Ove Holmström; Anette Stahel; Jenny Bengtsson; Dennis Larsson
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-14       Impact factor: 4.292

5.  Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance.

Authors:  David T Marshall; Stephen J Savage; Elizabeth Garrett-Mayer; Thomas E Keane; Bruce W Hollis; Ronald L Horst; Linda H Ambrose; Mark S Kindy; Sebastiano Gattoni-Celli
Journal:  J Clin Endocrinol Metab       Date:  2012-04-16       Impact factor: 5.958

6.  Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

Authors:  Tomasz M Beer; Christopher W Ryan; Peter M Venner; Daniel P Petrylak; Gurkamal S Chatta; J Dean Ruether; Charles H Redfern; Louis Fehrenbacher; Mansoor N Saleh; David M Waterhouse; Michael A Carducci; Daniel Vicario; Robert Dreicer; Celestia S Higano; Frederick R Ahmann; Kim N Chi; W David Henner; Alan Arroyo; Fong W Clow
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

7.  Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.

Authors:  Tony Choon Seng Woo; Richard Choo; Mary Jamieson; Sarat Chander; Reinhold Vieth
Journal:  Nutr Cancer       Date:  2005       Impact factor: 2.900

8.  Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer.

Authors:  Glenn Liu; George Wilding; Mary Jane Staab; Dorthea Horvath; Kelly Miller; Amy Dresen; Dona Alberti; Rhoda Arzoomanian; Rick Chappell; Howard H Bailey
Journal:  Clin Cancer Res       Date:  2003-09-15       Impact factor: 12.531

Review 9.  Vitamin D and prostate cancer.

Authors:  D Feldman; R J Skowronski; D M Peehl
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

Review 10.  Vitamin D and intervention trials in prostate cancer: from theory to therapy.

Authors:  Gary G Schwartz
Journal:  Ann Epidemiol       Date:  2008-07-10       Impact factor: 3.797

View more
  10 in total

1.  Systems analysis of the prostate transcriptome in African-American men compared with European-American men.

Authors:  Gary Hardiman; Stephen J Savage; E Starr Hazard; Robert C Wilson; Sean M Courtney; Michael T Smith; Bruce W Hollis; Chanita Hughes Halbert; Sebastiano Gattoni-Celli
Journal:  Pharmacogenomics       Date:  2016-06-30       Impact factor: 2.533

2.  Phosphorylation of Human Retinoid X Receptor α at Serine 260 Impairs Its Subcellular Localization, Receptor Interaction, Nuclear Mobility, and 1α,25-Dihydroxyvitamin D3-dependent DNA Binding in Ras-transformed Keratinocytes.

Authors:  Sylvester Jusu; John F Presley; Richard Kremer
Journal:  J Biol Chem       Date:  2016-11-16       Impact factor: 5.157

3.  Vitamin D Deficiency has no Impact on PSA Reference Ranges in a General University Hospital - A Retrospective Analysis.

Authors:  Zoltán Tóth; Balázs Szalay; Béla Gyarmati; Dlovan Ali Jalal; Barna Vásárhelyi; Tamás Szabó
Journal:  EJIFCC       Date:  2020-09-29

Review 4.  Nutrition, dietary interventions and prostate cancer: the latest evidence.

Authors:  Pao-Hwa Lin; William Aronson; Stephen J Freedland
Journal:  BMC Med       Date:  2015-01-08       Impact factor: 8.775

5.  Association among plasma 1,25(OH)2 D, ratio of 1,25(OH)2 D to 25(OH)D, and prostate cancer aggressiveness.

Authors:  Swathi Ramakrishnan; Susan E Steck; Lenore Arab; Hongmei Zhang; Jeannette T Bensen; Elizabeth T H Fontham; Candace S Johnson; James L Mohler; Gary J Smith; L Joseph Su; Anna Woloszynska
Journal:  Prostate       Date:  2019-05-11       Impact factor: 4.012

6.  Vitamin D sufficiency enhances differentiation of patient-derived prostate epithelial organoids.

Authors:  Tara McCray; Julian V Pacheco; Candice C Loitz; Jason Garcia; Bethany Baumann; Michael J Schlicht; Klara Valyi-Nagy; Michael R Abern; Larisa Nonn
Journal:  iScience       Date:  2021-01-05

Review 7.  Dietary Factors and Supplements Influencing Prostate Specific-Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials.

Authors:  Maria G Grammatikopoulou; Konstantinos Gkiouras; Stefanos Τ Papageorgiou; Ioannis Myrogiannis; Ioannis Mykoniatis; Theodora Papamitsou; Dimitrios P Bogdanos; Dimitrios G Goulis
Journal:  Nutrients       Date:  2020-09-29       Impact factor: 5.717

8.  Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP.

Authors:  Susan E Steck; Lenore Arab; Hongmei Zhang; Jeannette T Bensen; Elizabeth T H Fontham; Candace S Johnson; James L Mohler; Gary J Smith; Joseph L Su; Donald L Trump; Anna Woloszynska-Read
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

Review 9.  Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans.

Authors:  Ken Batai; Adam B Murphy; Larisa Nonn; Rick A Kittles
Journal:  Front Immunol       Date:  2016-02-22       Impact factor: 7.561

Review 10.  Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis.

Authors:  Zhen-Yu Song; Qiuming Yao; Zhiyuan Zhuo; Zhe Ma; Gang Chen
Journal:  Endocr Connect       Date:  2018-12-01       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.